Archives
-
3D Collagen Microtissues for Cancer Drug Testing
2026-09-13
A 2026 study introduces free-floating collagen microtissues produced by modular tissue engineering as a practical three-dimensional model for triple-negative breast cancer. The system spontaneously develops hypoxia, cell-line-dependent stemness phenotypes, and treatment resistance, providing a useful bridge between simple monolayers and more complex tumor models.
-
Everolimus (RAD001) Workflow for Cancer Assays
2026-09-12
Use Everolimus (RAD001) to connect mTOR pathway inhibition with distinct measurements of growth arrest and cell killing. This workflow combines dose-response profiling, time-resolved apoptosis assays, phospho-signaling checks, and translational interpretation for cancer models.
-
Recombinant Mouse IFN-γ for MASH-HCC Assay Design
2026-09-11
Recombinant Mouse IFN-γ can do more than restore MHC-I signal in MASH-HCC models. This guide presents a confounder-aware assay framework that separates cytokine responsiveness from genuine reversal of bile acid–driven immune escape.
-
Recombinant Annexin V for Apoptosis Detection
2026-09-11
Brumatti, Sheridan, and Martin describe a practical bacterial expression and purification workflow for soluble, polyhistidine-tagged recombinant annexin V. The study connects this reagent to FITC-based flow cytometry and fluorescence microscopy for detecting phosphatidylserine externalization, while emphasizing that membrane labeling is an early apoptosis-associated event rather than an isolated measure of terminal membrane rupture.
-
Nintedanib: Biomarker-Led RTK Translation
2026-09-10
Nintedanib (BIBF 1120) offers a mechanistically rich framework for connecting VEGFR, FGFR, and PDGFR inhibition with biomarker-led cancer and fibrosis research. This article translates ATRX-deficient glioma findings into practical assay strategy while defining the limits of current evidence.
-
Nose-to-Brain Rotigotine Nanoparticles for Parkinson’s
2026-09-10
The reference study developed rotigotine-loaded chitosan nanoparticles to address limited solubility, first-pass metabolism, and brain delivery challenges associated with conventional administration. In SH-SY5Y cells and a haloperidol-induced rat model, the formulation showed cellular compatibility, neuroprotective marker changes, improved motor-related outcomes, and evidence of enhanced brain targeting after intranasal dosing.
-
Dibutyryl-cAMP, Sodium Salt: Applied Workflows
2026-09-09
Dibutyryl-cAMP, sodium salt provides a practical way to raise intracellular cAMP and interrogate PKA-linked responses in live-cell, differentiation, inflammation, and neuronal assays. This guide combines an executable optimization workflow with lessons from human and mouse brain-slice research, while keeping cAMP perturbation distinct from NUAK-dependent tau biology.
-
Substance P (B6620): Reliable Assay Workflows
2026-09-09
A scenario-based guide to using Substance P (SKU B6620) in cell viability, proliferation, and cytotoxicity workflows. It connects peptide handling, assay compatibility, spectral-interference control, and vendor-selection criteria to practical laboratory decisions.
-
hsa_circ_0001944, FXR/TLR4, and Ferroptosis in Fibrosis
2026-09-08
A 2025 study in Toxics identifies hsa_circ_0001944 as a regulator of the FXR/TLR4 axis and ferroptosis during nickel oxide nanoparticle-induced collagen deposition in LX-2 hepatic stellate cells. Its pharmacological and genetic experiments connect reduced FXR signaling with TLR4 elevation, altered ferroptosis features, and fibrotic matrix production, providing a mechanistic framework for studying nanoparticle-associated liver injury.
-
Four-Factor Reprogramming of Astrocytes into Motoneurons
2026-09-08
The reference study identifies an Ascl1–Myt1l–Pou3f2–Isl1 transcription-factor cocktail that converts rat and human reactive astrocytes into motoneuron-like cells. Its main mechanistic insight is that reprogramming proceeds through neural progenitor-like and motor-neuron-progenitor-like intermediate states before acquisition of neuronal markers and selected motor-neuron functions.
-
Physiological and Pathological Aβ in Human Synapses
2026-09-07
This study uses live human brain slice cultures to distinguish how physiological amyloid-β and Alzheimer’s disease-associated amyloid-β affect synapses. Its findings show that changing physiological Aβ in either direction reduces synaptophysin puncta, whereas pathological Aβ-containing extract promotes postsynaptic uptake and presynaptic loss without the same transcript response.
-
Nuclear Export Combinations in Basal-Like TNBC
2026-09-07
The reference study used drug screening, synergy testing, patient-derived xenografts, and transcriptomic analyses to identify KPT-330-containing combinations for basal-like triple-negative breast cancer. Its strongest preclinical result was greater tumor burden reduction with KPT-330 plus GSK2126458 than with either monotherapy, while XPO1 expression emerged as a potential biomarker of aggressive disease.
-
Phosbind Biotin LC Western Blot Protocol
2026-09-05
Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes. It is suited to Western Blot workflows using streptavidin-HRP and chemiluminescence, but should not be used in aqueous-only protocols or for long-term storage of working solutions.
-
3D Proteomics and Carboplatin Response in HGSOC
2026-09-04
A 2025 Journal of Proteome Research study shows that 3D spheroid culture substantially reshapes the proteome of high-grade serous ovarian carcinoma models and changes their response to Carboplatin. Its paired cell-line design identifies energy-metabolism, membrane-associated, and NDUF-family signatures that can improve interpretation of preclinical drug-response experiments.
-
Probenecid Workflows for MDR and Neuroprotection
2026-09-04
Probenecid is a versatile research tool for testing transporter-mediated drug resistance, pannexin-1 biology, and injury-associated neuroinflammation. This applied guide connects practical oncology and cerebral ischemia/reperfusion workflows with a new CD8+ T-cell immunometabolism framework while emphasizing controls, assay selection, and troubleshooting.